Acción BRPA NRX PHARMACEUTICALS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas NRx Pharmaceuticals, Inc.

Acciones

BRPA

US6294442099

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 20:57:55 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
2,61 USD -26,48 % Gráfico intradía de NRx Pharmaceuticals, Inc. -13,48 % -42,63 %
14:30 NRx Pharmaceuticals, Inc. Anuncia Resultados Prometedores en el Ensayo Clínico de Fase 2B/3 de Nrx-101 Vs. Lurasidona para el tratamiento de la depresión bipolar suicida CI
18/04 Los fondos cotizados y los futuros de renta variable suben antes de la campana del jueves a la espera de los discursos de los responsables de la Fed MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
Top Premarket Decliners
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BRPA
  4. Noticias NRx Pharmaceuticals, Inc.
  5. Otros idiomas